Regeneron Pharmaceuticals (REGN) net assets (shareholders' equity)

Net assets · fiscal 2025
$31.26B

Regeneron Pharmaceuticals (REGN) had net assets of $31.26B at the end of fiscal 2025 (December 31, 2025). That is 6.5% higher than the $29.35B of fiscal 2024. Figures as of 18 Nov 2026, 19:11 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Net assets, fiscal 2025
$31.26B
Change on fiscal 2024
+6.5%
Growth, 5 years
+23.2% a year
Growth, 10 years
+23.9% a year
Highest on record
$31.26Bfiscal 2025
Lowest on record
$396.76Mfiscal 2009
Fiscal years on record
182008–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.

Regeneron Pharmaceuticals net assets (shareholders' equity), in more detail

Over the five fiscal years to 2025 net assets grew at a compound 23.2% a year; over ten years the rate was 23.9% a year. Across the 18 fiscal years on record (2008–2025), the highest was $31.26B in fiscal 2025 and the lowest $396.76M in fiscal 2009.

History · 18 fiscal years

Net assets by fiscal year

Regeneron Pharmaceuticals net assets (shareholders' equity), year by year

Regeneron Pharmaceuticals (REGN) net assets (shareholders' equity) by fiscal year
Fiscal yearNet assetsChangeYear ended
2025$31.26B 6.5% up
2024$29.35B 13.0% up
2023$25.97B 14.6% up
2022$22.66B 20.8% up
2021$18.77B 70.2% up
2020$11.03B 0.6% down
2019$11.09B 26.6% up
2018$8.76B 42.5% up
2017$6.14B 38.1% up
2016$4.45B 21.7% up
2015$3.65B 43.3% up
2014$2.55B 29.8% up
2013$1.96B 56.3% up
2012$1.26B 158.7% up
2011$485.73M 8.0% down
2010$527.82M 33.0% up
2009$396.76M 5.9% down
2008$421.51M—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Net assets is shareholders' equity on the balance sheet at the fiscal year-end: total assets minus total liabilities, also called book value.

How to read it

Large buybacks and write-offs shrink it without the business getting worse, so a falling or negative figure needs the reason before a verdict.

Net assets at health care companies of similar size

Net assets of Regeneron Pharmaceuticals and comparable companies
CompanyNet assetsFiscal year
Moderna MRNA$8.65B2025
CVS Health CVS$75.21B2025
HCA Healthcare HCA-$6.03B2025
GSK GSK£16.38B2025
Regeneron Pharmaceuticals REGN$31.26B2025
Elevance Health ELV$43.88B2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on REGN

Regeneron Pharmaceuticals, figure by figure

Regeneron Pharmaceuticals (REGN) overview: price, valuation and scorecardAll health care companies by market value

Regeneron Pharmaceuticals net assets (shareholders' equity): questions and answers

What are Regeneron Pharmaceuticals's net assets?

Regeneron Pharmaceuticals (REGN) had net assets of $31.26B at the end of fiscal 2025 (December 31, 2025). That is 6.5% higher than the $29.35B of fiscal 2024.

What is the growth rate of Regeneron Pharmaceuticals's net assets?

Over the five fiscal years to 2025 net assets grew at a compound 23.2% a year; over ten years the rate was 23.9% a year.

What are the highest and lowest net assets figures on record for Regeneron Pharmaceuticals?

Across the 18 fiscal years on record (2008–2025), the highest was $31.26B in fiscal 2025 and the lowest $396.76M in fiscal 2009.

How is Regeneron Pharmaceuticals's net assets calculated?

Net assets is shareholders' equity on the balance sheet at the fiscal year-end: total assets minus total liabilities, also called book value. For Regeneron Pharmaceuticals it is on record here for 18 fiscal years, 2008 to 2025.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Regeneron Pharmaceuticals (REGN) net assets (shareholders' equity)”, data as of 18 November 2026. https://funkfolio.com/stock/REGN/net-assets

Underlying data: the company's filings with the SEC and Yahoo Finance.